Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BUDD GT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 51 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Vaziri, SAJ; Krumroy, LM; Elson, P; Budd, GT; Darlington, G; Myles, J; Tubbs, RR; Casey, G
      Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis

      CLINICAL CANCER RESEARCH
    2. Olencki, T; Peereboom, D; Wood, L; Budd, GT; Novick, A; Finke, J; McLain, D; Elson, P; Bukowski, RM
      Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    3. Link, BK; Budd, GT; Scott, S; Dickman, E; Paul, D; Lawless, G; Fridman, M; Ford, J; Carter, WB
      Delivering adjuvant chemotherapy to women with early-stage breast carcinoma - Current patterns of care

      CANCER
    4. Olencki, T; Finke, J; Tubbs, R; Elson, P; McLain, D; Herzog, P; Budd, GT; Gunn, H; Bukowski, RM
      Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects

      JOURNAL OF IMMUNOTHERAPY
    5. van Stolk, R; Stoner, G; Hayton, WL; Chan, K; DeYoung, B; Kresty, L; Kemmenoe, BH; Elson, P; Rybicki, L; Church, J; Provencher, K; McLain, D; Hawk, E; Fryer, B; Kelloff, G; Ganapathi, R; Budd, GT
      Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis

      CLINICAL CANCER RESEARCH
    6. Pelley, R; Ganapathi, R; Wood, L; Rybicki, L; McLain, D; Budd, GT; Peereboom, D; Olencki, T; Bukowski, RM
      A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    7. Chidiac, T; Budd, GT; Pelley, R; Sandstrom, K; McLain, D; Elson, P; Crownover, R; Marks, K; Muschler, G; Joyce, M; Zehr, R; Bukowski, R
      Phase II trial of liposomal doxorubicin (Doxil (R)) in advanced soft tissue sarcomas

      INVESTIGATIONAL NEW DRUGS
    8. Bukowski, RM; Rayman, P; Molto, L; Tannenbaum, CS; Olencki, T; Peereboom, D; Tubbs, R; McLain, D; Budd, GT; Griffin, T; Novick, A; Hamilton, TA; Finke, J
      Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma

      CLINICAL CANCER RESEARCH
    9. Gurm, HS; Budd, GT
      A 47-year-old man with leiomyosarcoma and altered mental status

      CLEVELAND CLINIC JOURNAL OF MEDICINE
    10. Adelstein, DJ; Rice, TW; Rybicki, LA; Larto, MA; Koka, A; Taylor, ME; Olencki, TE; Peereboom, DM; Budd, GT
      Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    11. Budd, GT; Atiba, J; Silver, RT; Palmer, G; Armstrong, S; Otto, K; Presant, C
      Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    12. Budd, GT; Ganapathi, R; Wood, L; Snyder, J; McLain, D; Bukowski, RM
      Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine

      SEMINARS IN ONCOLOGY
    13. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    14. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    15. BUKOWSKI RM; RAYMAN P; UZZO R; BLOOM T; SANDSTROM K; PEEREBOOM D; OLENCKI T; BUDD GT; MCLAIN D; ELSON P; NOVICK A; FINKE JH
      SIGNAL-TRANSDUCTION ABNORMALITIES IN T-LYMPHOCYTES FROM PATIENTS WITHADVANCED RENAL-CARCINOMA - CLINICAL RELEVANCE AND EFFECTS OF CYTOKINETHERAPY

      Clinical cancer research
    16. BUKOWSKI RM; OLENCKI T; BOCOCK K; BUDD GT; PEEREBOOM D; MCLAIN D; GRIFFIN T
      PHASE-I TRIAL OF CAPECITABINE AND SUBCUTANEOUS INTERFERON-ALPHA IN RENAL-CELL CARCINOMA (RCC)

      Annals of oncology
    17. CHAN KK; ZHANG Z; CHEN H; GANAPATHI R; HAYTON W; ELSON P; HAWK E; KELLOFF G; BUDD GT
      CLINICAL PHARMACOKINETICS OF PERILLYL ALCOHOL (POH) AND METABOLITES FOLLOWING ORAL DOSING

      Annals of oncology
    18. TAYLOR CW; GREEN S; DALTON WS; MARTINO S; RECTOR D; INGLE JN; ROBERT NJ; BUDD GT; PARADELO JC; NATALE RB; BEARDEN JD; MAILLIARD JA; OSBORNE CK
      A MULTICENTER RANDOMIZED CLINICAL-TRIAL OF GOSERELIN VERSUS SURGICAL OVARIECTOMY IN PREMENOPAUSAL PATIENTS WITH RECEPTOR-POSITIVE METASTATIC BREAST-CANCER - AN INTERGROUP STUDY

      Journal of clinical oncology
    19. Rajagopalan, K; Peereboom, D; Budd, GT; Olencki, T; Murthy, S; Elson, P; McLain, D; Bukowski, R
      Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

      INVESTIGATIONAL NEW DRUGS
    20. VANSTOLK R; BUDD GT; KRESTY R; GANAPATHI R; ELSON P; CHURCH J; PIAZZA G; FRYER B; PROVENCHER K; PAMUKCU R; HAWK E; KELLOFF G; STONER G
      EFFECT OF SULINDAC SULFONE ON PROLIFERATION, APOPTOSIS, AND POLYPS INA CLINICAL-TRIAL IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS

      Gastroenterology
    21. BUKOWSKI RM; OLENCKI T; WANG Q; PEEREBOOM D; BUDD GT; ELSON P; SANDSTROM K; TUASON L; RAYMAN P; TUBBS R; MCLAIN D; KLEIN E; NOVICK A; FINKE J
      PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE

      Journal of immunotherapy with emphasis on tumor immunology
    22. RUSSELL CA; GREEN SJ; OSULLIVAN J; HYNES HE; BUDD GT; CONGDON JE; MARTINO S; OSBORNE CK
      MEGESTROL-ACETATE AND AMINOGLUTETHIMIDE HYDROCORTISONE IN SEQUENCE ORIN COMBINATION AS 2ND-LINE ENDOCRINE THERAPY OF ESTROGEN RECEPTOR-POSITIVE METASTATIC BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP PHASE-III TRIAL/

      Journal of clinical oncology
    23. PIAZZA GA; FRYER BH; VANSTOLK RU; BUDD GT; STONER GD; HAWK E; KELLOFF G; PAMUKCU R; AHNEN DJ; GANAPATHI R
      SELECTIVE APOPTOSIS OF NEOPLASTIC-CELLS ACCOMPANIES POLYP REGRESSION IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) PATIENTS TREATED WITH FGN-1 (SULINDAC SULFONE) - EVIDENCE FOR A CYCLOOXYGENASE INDEPENDENT MECHANISM

      Gastroenterology
    24. VANSTOLK RU; DEYOUNG B; CHURCH JM; GANAPATHI R; PROVENCHER K; STONER G; HAWK E; PAMUKCU R; KELLOFF G; BUDD GT
      CLINICOPATHOLOGICAL CORRELATION OF RECTAL ADENOMA REGRESSION IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TREATED WITH SULINDAC SULFONE IN A PHASE I II TRIAL/

      Gastroenterology
    25. VANSTOLK RU; BUDD GT; HAYTON W; ELSON P; PROVENCHER K; CHURCH JM; GANAPATHI R; STONER G; HAWK E; PAMUKCU R; KELLOFF G; CHAN K
      PHASE-I TRIAL OF SULINDAC SULFONE IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS - OPTIMAL DOSE AND SAFETY

      Gastroenterology
    26. BUDD GT; GANAPATHI R; ADELSTEIN DJ; PELLEY R; OLENCKI T; PETRUS J; MCLAIN D; ZHANG JL; CAPIZZI R; BUKOWSKI RM
      RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS

      Cancer
    27. MEYER JI; HERTS BR; EINSTEIN DM; SINGER AA; BUDD GT; COHEN MAH
      PELVIC COMPUTED-TOMOGRAPHY OF BREAST-CARCINOMA PATIENTS - SHOULD IT ROUTINELY BE ADDED TO ABDOMINAL COMPUTED-TOMOGRAPHY

      Cancer
    28. BUKOWSKI RM; OLENCKI T; GUNN H; MCLAIN D; BUDD GT; SANDSTROM K; TUASON L; REDOVAN C; RAYMAN P; TUBBS R; RESTA D; ELSON P; FINKE J
      PHASE-I TRIAL OF SUBCUTANEOUS INTERLEUKIN-3 IN PATIENTS WITH REFRACTORY MALIGNANCY - HEMATOLOGICAL, IMMUNOLOGICAL, AND PHARMACODYNAMIC FINDINGS

      Clinical cancer research
    29. OLENCKI T; FINKE J; TUBBS R; TUASON L; GREENE T; MCLAIN D; SWANSON SJ; HERZOG P; STANLEY T; EDINGER M; BUDD GT; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF INTERLEUKIN-2 AND INTERLEUKIN-4 IN PATIENTS WITH MALIGNANCY

      Journal of immunotherapy with emphasis on tumor immunology
    30. BUDD GT; GANAPATHI R; BUKOWSKI RM; MURTHY S
      CLINICAL EFFECTS OF AMIFOSTINE (ETHYOL(R)) IN PATIENTS TREATED WITH CARBOPLATIN

      European journal of cancer
    31. BUDD GT
      AMIFOSTINE AND CHEMOTHERAPY-RELATED THROMBOCYTOPENIA

      Seminars in oncology
    32. CONNELLY EF; BUDD GT
      IFOSFAMIDE IN THE TREATMENT OF SOFT-TISSUE SARCOMAS

      Seminars in oncology
    33. WOS E; OLENCKI T; TUASON L; BUDD GT; PEEREBOOM D; SANDSTROM K; MCLAIN D; FINKE J; BUKOWSKI RM
      PHASE-II TRIAL OF SUBCUTANEOUSLY ADMINISTERED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

      Cancer
    34. BUDD GT; SAMUELS B; GOCKERMAN J; BAKER L; MARGOLIN K; ZALUPSKI M; FELSER J; JOHNSON B; ISAACS R; BUKOWSKI RM
      RANDOMIZED TRIAL OF MAID (MESNA, ADRIAMYCIN, IFOSFAMIDE, DECARBAZINE)CHEMOTHERAPY WITH G-CSF ALONE OR WITH G-CSF PLUS VARYING DOSES OF INTERLEUKIN-6 (IL-6)

      Blood
    35. BUKOWSKI RM; DON W; REDOVAN C; MCLAIN D; SANDSTROM K; OLENCKI T; BUDD GT; PEEREBOOM D; GRIFFIN T; TANNENBAUM C; FINKE JK
      INDUCTION OF THE CXC CHEMOKINES IP-10 AND MIG IN PATIENTS (PTS) RECEIVING RHUIL-12 OR RIL-2

      Blood
    36. BUDD GT; GREEN S; OBRYAN RM; MARTINO S; ABELOFF MD; RINEHART JJ; HAHN R; HARRIS J; TORMEY D; OSULLIVAN J; OSBORNE CK
      SHORT-COURSE FAC-M VERSUS 1 YEAR OF CMFVP IN NODE-POSITIVE, HORMONE RECEPTOR-NEGATIVE BREAST-CANCER - AN INTERGROUP STUDY

      Journal of clinical oncology
    37. BUDD GT
      PALLIATIVE CHEMOTHERAPY OF ADULT SOFT-TISSUE SARCOMAS

      Seminars in oncology
    38. RICE TW; ADELSTEIN DJ; KOKA A; TEFFT M; KIRBY TJ; VANKIRK MA; TAYLOR ME; OLENCKI TE; PEEREBOOM D; BUDD GT
      ACCELERATED INDUCTION THERAPY AND RESECTION FOR POOR-PROGNOSIS STAGE-III NON-SMALL-CELL LUNG-CANCER

      The Annals of thoracic surgery
    39. BUKOWSKI RM; MURTHY SA; FINKE J; CAULFIELD MJ; TUBBS R; HERZOG P; STANLEY J; EDINGER M; TUASON L; MCLAIN D; BUDD GT; OLENCKI T; GANAPATHI R
      PHASE-I TRIAL OF CISPLATIN, WR-2721, AND THE MURINE MONOCLONAL-ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND BIOLOGIC EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    40. BUDD GT; LORENZI V; GANAPATHI R; ADELSTEIN D; PELLEY R; OLENCKI T; MCLAIN D; BUKOWSKI RM
      AMIFOSTINE - POTENTIAL FOR CLINICALLY USEFUL CYTOPROTECTION

      Supportive care in cancer
    41. BUKOWSKI RM; BUDD GT; GIBBONS JA; BAUER RJ; CHILDS A; ANTAL J; FINKE J; TUASON L; LORENZI V; MCLAIN D; TUBBS R; EDINGER M; THOMASSEN MJ
      PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT MACROPHAGE-COLONY-STIMULATING FACTOR - CLINICAL AND IMMUNOMODULATORY EFFECTS

      Journal of clinical oncology
    42. BHATIA A; RICE TW; MCLAIN D; HERZOG P; BUDD GT; MURTHY S; KIRBY TJ; BUKOWSKI RM
      A PHASE-I TRIAL OF INTRAPLEURAL RECOMBINANT HUMAN INTERFERON-ALPHA (RHUIFN-ALPHA-2B) IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

      Journal of cancer research and clinical oncology
    43. BUDD GT; HERZOG P; BUKOWSKI RM
      PHASE I II TRIAL OF DIPYRIDAMOLE, 5-FLUOROURACIL, LEUKOVORIN, AND MITOXANTRONE IN METASTATIC BREAST-CANCER/

      Investigational new drugs
    44. KARNIK PS; KULKARNI S; LIU XP; BUDD GT; BUKOWSKI RM
      ESTROGEN-RECEPTOR MUTATIONS IN TAMOXIFEN-RESISTANT BREAST-CANCER

      Cancer research
    45. BUKOWSKI RM; OLENCKI T; MCLAIN D; TUASON L; BUDD GT; SANDSTROM K; RAYMAN P; GUNN H; LEVITT D; FINKE J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT INTERLEUKIN-3 (RHIL-3) FOLLOWING SUBCUTANEOUS (SQ) ADMINISTRATION TO PATIENTS WITH REFRACTORY MALIGNANCIES

      Blood
    46. WOS E; OLENCKI T; BUDD GT; PEEREBOOM D; FINKE J; WOOD L; MCLAIN D; TUBBS R; REDOVAN C; EDINGER M; LEVITT D; BUKOWSKI RM
      HEMATOLOGIC EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHUGM-CSF) AND INTERLEUKIN-6 (RHIL-6) ADMINISTERED TO PATIENTS WITH MALIGNANCY

      Blood
    47. THOMASSEN MJ; ANTAL JM; CONNORS MJ; MCLAIN D; SANDSTROM K; MEEKER DP; BUDD GT; LEVITT D; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF RECOMBINANT INTERLEUKIN-3 TREATMENT ON HUMAN ALVEOLAR MACROPHAGES AND MONOCYTES

      Journal of immunotherapy with emphasis on tumor immunology
    48. BUKOWSKI RM; MURTHY S; MCLAIN D; FINKE J; ANDRESEN S; TUBBS R; BAUER L; GIBSON V; BUDD GT; THOMASSEN MJ
      PHASE-I TRIAL OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH LUNG-CANCER - CLINICAL AND IMMUNOLOGICAL EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    49. BUDD GT; GANAPATHI R; BAUER L; MURTHY S; ADELSTEIN D; WEICK J; GIBSON V; MCLAIN D; SERGI J; BUKOWSKI RM
      PHASE-I STUDY OF WR-2721 AND CARBOPLATIN

      European journal of cancer
    50. BUDD GT; BUKOWSKI RM; LICHTIN A; BAUER L; VANKIRK P; GANAPATHI R
      PHASE-II TRIAL OF DOXORUBICIN AND TRIFLUOPERAZINE IN METASTATIC BREAST-CANCER

      Investigational new drugs
    51. OLENCKI T; BUDD GT; MURTHY S; FINKE J; HERZOG P; MCLAIN D; TUBBS R; TUASON L; EDINGER M; LEVITT D; BUKOWSKI RM
      CYTOKINE GENE-EXPRESSION AND SECRETION - EFFECTS OF RHIL-6 IN CANCER-PATIENTS

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 01:06:56